Acino Pharma currently employs around 500 people in the canton of Basel-Landschaft in two locations: Aesch and Liesberg, according to a newsletter from the Canton of Basel-Landschaft Economic Promotion. The investments in the amount of EUR 25 million (CHF 27 million) to EUR 30 million will ensure job security and also maintain the company’s competitive edge.
The investments in Switzerland are in line with Acino’s strategy to grow its business by entering new markets. In addition to selected markets in the Middle East, Africa and Latin America, the company entered the CIS region in December 2014 after it acquired Copharm. In October 2015 Acino announced the acquisition of Pharma Start, a Ukrainian pharmaceutical company, which will allow Acino to roll out its combined portfolio in Ukraine as well as to markets in Russia, Belarus, Kazakhstan and Uzbekistan.
Acino supplies finished in-house developed products and also provides customised one-stop solutions from product development and registration to contract manufacturing, packaging and logistics, writes the company in its news release. Under the brand “Acino Switzerland”, it markets Swiss quality medicines in emerging markets.